MDT · Q4 2025 Earnings
CautiousMedtronic
Reported May 21, 2025
30-second summary
Q4 organic revenue grew 5.4% to $8.93B with non-GAAP EPS of $1.62, and management announced the separation of the Diabetes business via capital markets transactions — framed as a margin-accretive portfolio move that lifts ex-Diabetes adjusted gross and operating margins by ~50bps and ~100bps respectively. FY26 EPS guidance of $5.50–$5.60 brackets a $200–350M tariff COGS headwind, with the low end assuming bilateral US/China tariffs snap back after the 90-day pause. Underlying growth drivers (PFA/CAS at ~30%, structural heart, neuromodulation, Hugo) are accelerating, but the FY26 EPS midpoint implies roughly 1% growth on a reported basis — the tariff overlay is doing real damage to the optical print.
Headline numbers
EPS
Q4 FY2025
$1.62
Revenue
Q4 FY2025
$8.93B
+5.4% YoY
Gross margin
Q4 FY2025
65.1%
Operating margin
Q4 FY2025
27.8%
Key financials
Q4 FY2025| Metric | Q4 FY2025 | YoY |
|---|---|---|
| Revenue | $8.93B | +5.4% |
| EPS | $1.62 | — |
| Gross margin | 65.1% | — |
| Operating margin | 27.8% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| Cardiovascular | $3.336B | +7.8% |
| Cardiac Rhythm & Heart Failure | $1.733B | +10.3% |
| Structural Heart & Aortic | $0.944B | +8.3% |
| Coronary & Peripheral Vascular | $0.659B | +1.0% |
| Neuroscience | $2.62B | +3.7% |
| Cranial & Spinal Technologies | $1.342B | +4.4% |
| Specialty Therapies | $0.759B | -1.6% |
| Neuromodulation | $0.52B | +10.2% |
| Medical Surgical | $2.212B | +2.0% |
| Surgical & Endoscopy | $1.709B | +1.7% |
| Acute Care & Monitoring | $0.503B | +3.1% |
| Diabetes | $0.728B | +12.0% |
Other KPIs
Q4 FY2025| Segment | Q4 FY2025 | YoY |
|---|---|---|
| U.S. | $4.547B | +4.9% |
| International | $4.38B | +5.8% |
| Cardiac Ablation Solutions Growth | ~30% | — |
| Cardiac Rhythm Management Growth | high-single digit | — |
| Structural Heart Growth | low-double digit | — |
| Neuromodulation Growth | low-double digit | — |
| Diabetes Organic Growth | 12.0% | — |
| Free Cash Flow Conversion | 73% | — |
| Operating Cash Flow | $7.044 billion | — |
| Shareholder Returns | $6.3 billion | — |
Management tone
The Q4 call was the most strategically aggressive Medtronic communication in years. Three shifts stand out.
Diabetes recategorized from core integrated business to separable non-core asset. For years Medtronic has defended its diversified medtech model. This quarter management announced separation via capital markets transactions, with explicit margin math: "Diabetes has lower gross margins and operating margins than overall Medtronic. So upon full separation, we're expecting our adjusted gross and operating margins to improve by approximately 50 and 100 basis points respectively." The framing — Diabetes is healthy enough to stand alone after six quarters of double-digit growth, and worth more outside — is a notable departure from the prior "integrated platform" narrative. Read this as management prioritizing structural margin expansion and capital reallocation over revenue growth optics.
R&D acceleration breaks a four-year pattern. Management stated plainly: "For the first time in four years, we're planning to grow R&D faster than revenue." Combined with the diabetes separation, this signals a company willing to take optical earnings pressure in FY26 to fund the next growth cycle (PFA, Hugo, Ardian/RDN, closed-loop neuromodulation).
CAS and Hugo elevated from "emerging" to "core strategic." Last year these were future-tense; this quarter CAS is at $1B with a doubling target, Hugo is in 30 countries with multiple FDA filings pending, and structural heart is described as winning share rather than tracking the market. The quoted line — "The underlying fundamentals of our business are strong, and they are getting stronger" — was repeated, signaling confidence that the tariff/FX noise is masking real operational momentum.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Robbie Marcus · J.P. Morgan
If FY27 high single-digit EPS growth excludes one-time benefits (favorable FX, diabetes spin share buyback), would FY27 still achieve high single-digit EPS growth on fundamental operations alone?
Management affirmed that fundamentals support high single-digit EPS growth in FY27 regardless of transaction benefits. They highlighted Q4 organic revenue growth of 5.4% with 200 bps operating margin expansion (excluding FX), 15.8% EPS growth ex-FX, and emphasized that the 27 target is for teams to deliver on framework independent of the diabetes transaction. FX is assumed flat in guidance, not as a tailwind.
Vijay Kumar · Evercore
Why is FY26 earnings growth back-end loaded despite 7% operating profit growth? What drove Q4 gross margin underperformance? Can management commit to EPS growing above revenues regardless of FX environment?
Management explained back-end loading is due to: Q1 seasonally lower absorption, increased R&D investment ahead of returns, and FX headwind in Q1 turning tailwind later. Gross margin was pressured 80 bps by mix (CAS and Simplera diabetes), offset by pricing and cost gains. Committed to EPS growth above revenue through structural FX hedges, dynamic pricing in devaluing currencies, and natural operational hedges, independent of FX direction.
Larry Bagelson · Wells Fargo
Why spin only diabetes when the remaining three businesses have different customers and capital requirements? Why divest a business growing above corporate average?
Management emphasized diabetes turnaround is complete and ready to stand alone; the spin allows focused funding and access to public markets for growth. For Medtronic, it enables focus on higher-margin growth drivers (CV, Neuro, Surgical) aligned with core tech and healthcare system channels. Management suggested diabetes may be worth more outside the company. Remainder of company has strong synergies and robust growth drivers across portfolios.
Joanne Wench · Citi
What preparation are hospitals making for renal denervation reimbursement and how should investors model the revenue ramp?
Hospitals are opening RDN centers, training physicians, establishing coding/billing education, and building patient pathways. Large health systems proactively partnering with Medtronic on hypertension clinics. Ramp is longer than procedure replacements (e.g., PFA) because of need to rule out secondary hypertension causes, but represents a massive patient population and long-duration annuity growth driver.
Matt Mixick · Barclays
On spine: how does Medtronic's like-for-like growth compare to pure-play spine competitors and what is the underlying market growth rate?
Medtronic has achieved competitive differentiation through integrated enabling technology ecosystem (branded as 'Able', AI-enabled), moving from product story to solution story. Market demand is stable; competitors have exited due to investment intensity. Medtronic's competitive advantage is durable. Enabling technology growing strongly; customers upgrading from products to broader ecosystem (non-linear upgrade pattern). Several competitors have recently 'tapped out'.
What to watch into next quarter
Diabetes separation mechanics and timeline. Management said "series of capital market transactions" but provided no firm date, structure (spin vs. split-off vs. IPO), or proceeds use. Watch for clarification on Q1 FY26 call, plus any signal that the 50/100bps margin accretion math holds up under detailed disclosure.
CAS revenue run-rate vs. the doubling-from-$1B trajectory. Management framed doubling as near-term — Jeff said "it's not far off… the next couple of, you know, maybe, I don't know if it will exactly happen in the fiscal year, but, you know, we're in that ballpark." Watch whether quarterly CAS revenue exits FY26 at a pace consistent with $2B within ~4–6 quarters. Anything below ~25% YoY would dent the narrative.
Tariff resolution and the $200–350M COGS headwind. The EPS range hinges entirely on US/China bilateral tariff status post-90-day-pause. Watch for guidance updates if rates change materially mid-year — and whether the ~4% ex-tariff EPS growth holds as a clean underlying number.
Gross margin stabilization. Q4 65.1% was -70bps YoY on CAS/Simplera mix. Watch Q1 FY26 GM print — Simplera ramp will continue to pressure early quarters, so a sub-65% print would suggest the mix headwind is worse than framed.
Hugo US urology approval timing. Filed last quarter and refiled emphasis this quarter; an FDA action would be the first major US robotics catalyst and validates the multi-indication strategy (hernia, benign GYN to follow).
R&D-faster-than-revenue execution. Management committed to R&D growth above revenue for the first time in four years. Watch whether the FY26 R&D growth rate clears the ~5% revenue growth bar with room to spare, and whether operating margin still expands "materially faster than revenue" as promised.
Sources
- Medtronic FY25 Q4 Earnings Release (SEC 8-K Exhibit 99.1), filed 2025-05-21 — https://www.sec.gov/Archives/edgar/data/1613103/000161310325000078/exhibit991-fy25q4earningsr.htm
- Medtronic FY25 Q4 management prepared commentary (excerpts available alongside press release)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.